Trial Profile
A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2016
Price :
$35
*
At a glance
- Drugs Epirubicin (Primary) ; Ixabepilone (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 12 May 2009 Actual patient number changed from 35 to 42 as reported by ClinicalTrials.gov.
- 25 Feb 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 25 Feb 2009 Actual patient number (35) added as reported by ClinicalTrials.gov.